BCL2 and diffuse large B-cell lymphoma: A post-hoc analysis of the SADAL study by DLBCL subtypes revealed a higher ORR and longer median OS in DLBCL patients with normal c-MYC/BCL2 expression levels compared to those with c-MYC and BCL2 overexpression (46.2% vs. 14.8% and 13.7 vs. 5.1 months, respectively) [176].